Central nervous system failure in melanoma patients: Results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens

British Journal of Cancer

Volumn 104, Issue 12, 2011, Pages 1816-1821

  Chiarion Sileni, V ^a   Guida, M ^b   Ridolfi, L ^c   Romanini, A ^d   Del Bianco, P ^a   Pigozzo, J ^a   Brugnara, S ^e   Colucci, G ^b   Ridolfi, R ^c   De Salvo, G L ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e SANTA CHIARA HOSPITAL   (Italy)

Author keywords

advanced melanoma; brain metastasis; dacarbazine; randomised clinical trial; temozolomide

Indexed keywords

CISPLATIN; CREATININE; DACARBAZINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER INCIDENCE; CENTRAL NERVOUS SYSTEM METASTASIS; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 79958177869     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.178     Document Type: Article

References (28)

1. Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW (2002) A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 8(10): 3075-3081 (Pubitemid 35155016)
2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7): 2105-2116 (Pubitemid 29318842)
3. Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H (2005) Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 16(6): 950-957 (Pubitemid 40903922)
4. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16): 3635-3648 (Pubitemid 32786276)
5. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14): 2865-2872 (Pubitemid 41079905)
6. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12): 2972-2977 (Pubitemid 36676250)
7. Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23(6): 488-496
8. Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG (1999) A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5(7): 1629-1637 (Pubitemid 29334438)
9. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38(9): 1277-1287 (Pubitemid 20266126)
10. D'Atri S, Graziani G, Lacal PM, Nistico V, Gilberti S, Faraoni I, Watson AJ, Bonmassar E, Margison GP (2000) Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294(2): 664-671 (Pubitemid 30490843)
11. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20(8): 2045-2052 (Pubitemid 34408794)
12. Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25(16): 2306-2312
13. Gonzalez Cao M, Malvehy J, Marti R, Conill C, Sanchez M, Martin M, Carrera C, Herrero J, Gascon P, Mellado B, Castel T, Puig S (2006) Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. Melanoma res 16(1): 59-64 (Pubitemid 44133052)
14. Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16: 1141-1154
15. Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ (2006) Melanoma. J Natl Compr Canc Netw 4(7): 666-684
16. Ives NJ, Stowe RL, Lorigan P, Wheatley K (2007) Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25(34): 5426-5434 (Pubitemid 350232219)
17. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1): 158-166 (Pubitemid 30036349)
18. Ono M, Ando M, Yunokawa M, Nakano E, Yonemori K, Matsumoto K, Kouno T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y (2009) Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol 14(1): 48-52
19. Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH, Thatcher N, Middleton MR (2002) Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma res 12(2): 175-178 (Pubitemid 34478459)
20. Piccioni D, D'Atri S, Papa G, Caravita T, Franchi A, Bonmassar E, Graziani G (1995) Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 7(3): 224-229
21. Ready N, Aronson F, Wanebo H, Kennedy T (2005) A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma. Am J Clin Oncol 28(5): 479-484 (Pubitemid 41437387)
22. Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O (2002) Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20(6): 1600-1607 (Pubitemid 34260541)
23. Ridolfi R, Romanini A, Sileni VC, Michiara M, Guida M, Biasco G, Poletti P, Amaducci L, Leoni M, Ravaioli A (2004) Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma res 14(4): 295-299 (Pubitemid 39159143)
24. Ron IG, Sarid D, Ryvo L, Sapir EE, Schneebaum S, Metser U, Asna N, Inbar MJ, Safra T (2006) A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. Melanoma res 16(1): 65-69 (Pubitemid 44133053)
25. Toth K, Vaughan MM, Peress NS, Slocum HK, Rustum YM (1996) MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 149(3): 853-858 (Pubitemid 26334169)
26. Weber RW, O'Day S, Rose M, Deck R, Ames P, Good J, Meyer J, Allen R, Trautvetter S, Timmerman M, Cruickshank S, Cook M, Gonzalez R, Spitler LE (2005) Low-dose outpatient chemobiotherapy with temozo-lomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 23(35): 8992-9000 (Pubitemid 46211483)
27. Wen PY, Black PM, Loeffler JS (2001) Treatment of metastatic cancer. In Cancer: Principles & Practice of Oncology DeVita Jr VT, Hellman S, Rosenberg SA (eds) 6th edn, pp 2655-2670. Lippincott, Williams & Wilkins: Philadelphia, PA
28. Wierzbicka-Hainaut E, Sassolas B, Mourey L, Guillot B, Bedane C, Guillet G, Tourani JM (2010) Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial. Melanoma res 20(2): 141-146 (Pubitemid 351398269)